Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
it needs confirmation of one or two of those 'big' US companies to help this along and to get away from the covid stuff a little. If they are as good as LR reckons then maybe investors will see there is life after covid.
What's happening with the other 3 govt Lot contracts or USA commercial news, ffs
Delays and radio silence
Christ. I should have sold more
Dropping even further!
Same old story.
Needs real material news with names and numbers!!!
I bet the 800k buyer wished they had waited a little while. MY my, those stale bulls are determined today. Hopefully gone for good.
Yes Steve.
A positive update and good prospects eventually.
I take heart in that for the core holding I will have once reduced. I'd love reduce to hedge from market crash and see us breach 20p one day. That would be great as no crying over missed profits when the strategy for today is absolutely not to be over invested.
The H1 number coming in at £17.5m is a nice surprise compared to the “at least £15m” guidance given last month. Even though there was the slip indicating it was likely to be near £16m, that’s still another 10% on top of the £16m
A very solid H1. At the start of the year, who would have expected a £17.5m H1?
With the delta plus variant gathering traction, I would expect the sequencing work to maintain revenues on the DHSC contract for some time even if the basic PCR processing tails off! Core business and the US contracts coming online should support the FY22 £27m estimate with minimal covid testing anyway!
Yourgene has experienced strong demand for its Covid-19 tests, which propelled H1’22 revenues to £17.5m, ahead of the >£15.0m indicated at the AGM last month. This is more than double the revenues booked in H1’21 and close to the whole of FY21. Both Genomic Services and Genomic Technologies grew strongly in the period, with Covid-related revenues now acting as much more than a natural hedge in both segments. Despite the ongoing uncertainties and lack of forward visibility around Covid-testing volumes, we nudge up our FY22E revenue assumptions by £2.0m to £27.0m but prudently leave our profit forecasts unchanged. Our FY23E and beyond forecasts are also unchanged, underpinned by the positive outlook and strong pipeline of business in the US in particular, which we expect to contribute materially from next year onwards.